Pictet's $103.05B Q4 2025 U.S. Book Barely Budged. That's What Makes It Interesting.
Pictet Asset Management Holding SA kept its Q4 2025 13F book near record highs while refining, rather than abandoning, a quality-growth and healthcare-heavy portfolio.
Pictet Asset Management Holding SA did not use Q4 2025 to reinvent its U.S. equity book. It used the quarter to clarify it. The Swiss private-bank and asset-management group reported $103.05B of 13F AUM, essentially flat from Q3's $103.78B, while keeping the core of the portfolio anchored in the same quality-growth franchises that have defined the AI era: NVDA, MSFT, GOOGL, AAPL, AMZN, and AVGO.
TL;DR
- Pictet reported $103.05B of Q4 2025 13F AUM, only slightly below $103.78B in Q3.
- The disclosed holdings dataset used in this article totaled $98.43B, down just 1.0% quarter over quarter.
- Top holdings still centered on NVDA, MSFT, GOOGL, AAPL, AMZN, and AVGO.
- The quarter's message was subtle rotation: trims in some mature winners, adds in others, and a broader opportunity set without a break from the quality-growth template.
Why a nearly flat quarter can still be revealing
Pictet Asset Management Holding SA is not a tactical day-trading shop, and its filings usually need to be read with that in mind. The parent group entered 2026 highlighting record assets under management or custody of CHF 757B and CHF 19B of net new money in 2025. Against that backdrop, the U.S. 13F book did not need to swing dramatically to send a signal. The signal is that Pictet stayed close to the peak, expanded the number of holdings, and still chose to keep its heaviest disclosed bets in secular compounders rather than move defensively.
Pictet's largest U.S. holdings still centered on quality growth in Q4 2025
That matters because Q4 2025 was a quarter when many managers were forced to choose between staying with expensive AI-linked winners or rotating harder into laggards. Pictet largely stayed with the winners, but it did so in a measured way. GOOGL and KLAC were trimmed, while AMZN and AVGO were increased. That is not capitulation on the theme. It is portfolio maintenance.
Top holdings table: a quality-growth spine with healthcare ballast
| Ticker | Value | Weight | QoQ status |
|---|---|---|---|
| NVDA | $4.72B | 4.80% | Held roughly flat |
| MSFT | $3.57B | 3.63% | Held roughly flat |
| GOOGL | $2.69B | 2.74% | -13% shares |
| AAPL | $2.40B | 2.44% | Held roughly flat |
| AMZN | $2.27B | 2.31% | +11% shares |
| AVGO | $2.18B | 2.22% | +17% shares |
| TMO | $1.43B | 1.45% | -15% shares |
| META | $1.13B | 1.14% | Held roughly flat |
The shape of that table is classic Pictet. Technology dominates, but healthcare is not an afterthought. Thermo Fisher and LLY helped keep defensive growth in the mix, which is exactly what you would expect from a global asset manager that has spent years building thematic and multi-asset credibility, not just chasing the hottest single trade.
Sector allocation table: the top book still leaned to technology, but not only technology
| Sector bucket | Value in top 15 holdings | Examples | Read-through |
|---|---|---|---|
| Technology | $13.91B | NVDA, MSFT, AAPL, AVGO, KLAC, CRM | Technology remained the undisputed center of gravity. |
| Healthcare | $4.47B | TMO, LLY, ECL-related life-science exposure | Pictet kept a meaningful quality-defensive sleeve beside AI infrastructure. |
| Communication services | $3.64B | GOOGL, GOOG, META | Digital platform exposure remained important even with selective trims. |
| Consumer cyclical | $2.27B | AMZN | Consumer growth stayed in the book through global scale leaders. |
| Other international listings | $3.79B | Large non-U.S. names deeper in the visible top tier | The portfolio was broader than a pure U.S. mega-cap clone. |
QoQ changes table: quiet headline, meaningful calibration
| Move | Ticker | Share change | Q4 value | Interpretation |
|---|---|---|---|---|
| Increase | NFLX | +1117% | $562.3M | Pictet was willing to add aggressively to proven platform growth outside its very top tier. |
| Increase | NOW | +613% | $588.3M | Software and workflow automation remained aligned with Pictet's innovation bias. |
| Increase | ANET | +311% | $298.9M | Networking infrastructure linked naturally with the AI supply chain. |
| Increase | AEP | +374% | $135.5M | Even utility exposure can be read as an AI-power infrastructure hedge. |
| Decrease | KLAC | -23% | $1.08B | Pictet trimmed some semiconductor-tool exposure without leaving the theme. |
| Decrease | GOOGL | -13% | $2.69B | Alphabet was moderated, not abandoned. |
| Decrease | TMO | -15% | $1.43B | Healthcare ballast was calibrated lower, but stayed significant. |
Pictet's disclosed U.S. 13F value stayed near record highs into Q4 2025
The history chart makes the broader point. Pictet's reported 13F AUM rose from $90.02B in Q1 2025 to $103.78B in Q3, then slipped only modestly to $103.05B in Q4. That is not a risk-off break. It is what a mature, globally diversified allocator often looks like when it is digesting gains rather than chasing the next turn in the market.
What did Pictet buy in Q4 2025?
Pictet added 36 new positions in the article dataset, including CWST, HYG, EL, PRAX, ARWR, and NRG. That breadth matters. It suggests the quarter was not only about mega-cap concentration. Pictet was still probing for opportunities around the edges while keeping its largest capital commitments in proven franchises.
What did Pictet sell or trim?
Exits such as POOL, LULU, and IBKR show the manager cleaning up smaller positions, while the sharpest trims in FIS, EXC, and FOLD suggest Pictet was willing to recycle capital rather than let legacy names linger. The important point is that those trims did not translate into a wholesale retreat from growth leadership.
Analyst takeaway
Pictet's Q4 2025 filing is a good reminder that “flat” does not mean “inactive.” The manager held its U.S. 13F book near record size, broadened position count, and kept the portfolio's center of gravity in the same quality-growth and healthcare names that fit its global, research-driven identity. For readers who want a one-line summary: Pictet did not de-risk the AI era — it refined its exposure to it.
Keep exploring
Related Research
Explore all researchJanus Henderson kept Nvidia and Microsoft on top in Q4 2025, but the more interesting signal was underneath: new exposure to Intuitive Surgical, Protagonist Therapeutics and other growth-healthcare names. The next filing will show whether that rotation keeps building.
Apr 17, 2026
CalPERS used Q4 2025 to keep broad-market exposure high through VOO while still adding to Nvidia, Microsoft, Alphabet and Broadcom. The next filing will show whether the pension giant keeps that simple beta-heavy structure or rotates again.
Apr 17, 2026
American Century’s Q4 2025 filing kept Nvidia and Microsoft on top, but the more revealing changes were the big Netflix increase, fresh utility and industrial additions, and a continued AI-heavy core. The next filing will show whether those side bets keep scaling.
Apr 17, 2026
Nuveen’s Q4 2025 filing stayed large-cap and AI-heavy at the top, but the more revealing addition was a sizable fixed-income sleeve through NXUS and NHYB. The next filing will show whether those credit and bond ETFs remain central or fade back out.
Apr 17, 2026
Fisher’s Q4 2025 filing was still packed with mega-cap tech, but the bigger tell was a giant Treasury and investment-grade corporate bond sleeve built through IEF and VCIT. The next filing will show whether that duration bet was tactical or structural.
Apr 17, 2026